Click Therapeutics has announced a collaboration with Indivior to develop and commercialise prescription digital therapeutics for treating substance use disorders, starting with Opioid Use Disorder (OUD).
The collaboration aims to address gaps in OUD treatment, such as limited access to personalised psychosocial treatment. The primary product, CT-102, will utilise behavioural therapy and AI-enabled neuromodulatory interventions through a mobile application to deliver personalised care to OUD patients.
The development process will be patient-centric and evidence-based, with Click Therapeutics leading the development efforts. The collaboration will leverage Click's expertise in engaging patients with addiction and Indivior's experience in commercialising treatments for substance use disorders. The initial phase will focus on defining the product scope to meet the needs of patients, providers, and payers, with more details expected in 2024.
Under the agreement, Click Therapeutics will handle technical and clinical development, regulatory filings, and technical services for CT-102, while Indivior will receive a global license to commercialise the product.
Click Therapeutics will receive upfront license and early development payments, potential additional payments tied to regulatory and commercial milestones, and double-digit royalties on global sales. There is also the possibility of expanding the collaboration with additional products in the future.
Click here to read the original news story.